Wells Fargo analyst Yanan Zhu assumed coverage of Autolus Therapeutics with an Overweight rating and $8 price target, with no changes made to rating or target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AUTL:
- Autolus Therapeutics initiated with a Buy at Bryan Garnier
- Autolus Therapeutics management to meet with Truist
- Autolus Therapeutics CFO Lucinda Crabtree to step down
- Autolus Therapeutics announces resignation of Chief Financial Officer
- Autolus Therapeutics reports no business relationship with Silicon Valley Bank
